Skip to main content

Palbociclib use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Oct 7, 2024.

Drugs containing Palbociclib: Ibrance

Palbociclib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of palbociclib during breastfeeding. Because palbociclib is 85% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 29 hours and the manufacturer recommends that breastfeeding be discontinued during palbociclib therapy and for 3 weeks after the last dose. Palbociclib is also given in combination with letrozole or fulvestrant, which may increase the risk to the infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Palbociclib

CAS Registry Number

571190-30-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.